Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Inclusion Criteria: * Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent. * Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented SCC of the cervical lymph nodes, with unknown primaries. * \>10 pack years of tobacco use * Age ≥ 18 years * ECOG performance status ≤ 2 * At least one site of measurable disease * Adequate bone marrow function as shown by: ANC \> 1.5 x 109/L, Platelets \>100 x 109/L, Hb \>9 g/dL * Total calcium (corrected for serum albumin) within normal limits * Magnesium ≥ the lower limit of normal * Potassium within normal limits for the institution. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range * Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome) * Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min * Serum amylase ≤ ULN * Serum lipase ≤ ULN * Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L) * Signed informed consent * INR ≤ 2 Exclusion Criteria: * Distant metastatic disease * Less than or equal to 10 pack years of tobacco history * Received prior chemotherapy * Received prior radiation to the head and neck or adjacent anatomical site * Received prior treatment with a P13K i…